SIONNA THERAPEUTICS
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
SIONNA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Medical Pharmaceutical Therapeutics
Founded:
2018-01-01
Address:
Natick, Massachusetts, United States
Country:
United States
Website Url:
http://www.sionnatx.com
Total Employee:
11+
Status:
Active
Contact:
617-819-2020
Email Addresses:
[email protected]
Total Funding:
110 M USD
Current Advisors List
Investors List
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Series B - Sionna Therapeutics
TPG Rise Climate Fund
TPG Rise Climate Fund investment in Series B - Sionna Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Sionna Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Sionna Therapeutics
T. Rowe Price
T. Rowe Price investment in Series B - Sionna Therapeutics
OrbiMed
OrbiMed investment in Series B - Sionna Therapeutics
Official Site Inspections
http://www.sionnatx.com
- Host name: 248.236.154.104.bc.googleusercontent.com
- IP address: 104.154.236.248
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Sionna Therapeutics"
About Us - Sionna Therapeutics
Sionna Therapeutics was founded in 2019 to continue to explore novel approaches to treating CF by targeting NBD1. Leveraging more than a decade of large pharma scientific investment and extensive research on the NBD1 target …See details»
Sionna Therapeutics - LinkedIn
This individual will also be responsible for collaborating with internal teams, external vendors, and stakeholders across clinical programs, ensuring compliance with regulatory standards and the ...See details»
Sionna Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 617-819-2020 Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise.See details»
Investor Relations - Sionna Therapeutics, Inc
Nov 18, 2024 Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel …See details»
Senior Director/VP, New Product Planning & Competitive …
Experience as a member of the sales, marketing or market access & reimbursement organization or have led the launch and management of a new drug or new indication of an existing drug. …See details»
Release Details - investors.sionnatx.com
5 days ago BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the …See details»
SEC Filings - Sionna Therapeutics, Inc - investors.sionnatx.com
5 days ago View financial statements and other formal documents submitted to the U.S. Securities and Exchange Commission (SEC) for Sionna Therapeutics, Inc.See details»
Sionna Therapeutics, Inc. (SION) - Stock Analysis
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel …See details»
Sionna Therapeutics Announces Appointment of Jennifer …
Jun 3, 2024 Ms. Fitzpatrick most recently served as Vice President, Corporate Counsel at Sage Therapeutics, where she built and led a team providing legal counsel and contracting support …See details»
Sionna 2025 Company Profile: Valuation, Funding & Investors
Sionna General Information Description. Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for …See details»
Mike Cloonan - President & CEO at Sionna Therapeutics - The Org
During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the company’s first product, and the execution of a …See details»
Release Details - investors.sionnatx.com
Jan 8, 2025 – Dr. Ruddy, a CMO and pulmonologist, and Dr. Viney, a CEO and scientific leader, join Sionna with decades of experience in drug development – Boston, MA, January 8, 2025 …See details»
Sionna Therapeutics Company Profile | Management and
Www.sionnatx.com Sionna Therapeutics Profile and History Sionna Therapeutics is a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF.See details»
Associate Director, Human Resources - Sionna Therapeutics
We are accepting resumes for the position at [email protected]. Key Responsibilities: HR Compliance and Legal Adherence. Ensure compliance with federal and state HR regulations, …See details»
Career | Research Assistant/Associate Scientist | Sionna Therapeutics
Email: [email protected] Website: www.sionnatx.com Company Address: 21 Hickory Drive, Suite 500, Waltham, MA, 02451 About Sionna Therapeutics Dedicated to delivering therapies …See details»
Sionna Therapeutics - Company Profile & Staff Directory
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small …See details»
Sionna Therapeutics, Inc. (SION) - Stock Analysis
4 days ago About SION. Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by …See details»
CEO and Executive Team - The Org
Sionna Therapeutics' CEO and Executive Team includes Mike Cloonan and 4 others.See details»
Sionna Therapeutics Company Profile -Sales, Contacts, …
This organization has been operating for approximately 6 years. Sionna Therapeutics is estimated to generate $5.5 million in annual revenues, and employs approximately 22 people at this …See details»
Series B - Sionna Therapeutics - 2022-04-19 - Crunchbase
Apr 19, 2022 Organization Name . Sionna Therapeutics . Announced Date Apr 19, 2022; Funding Type Series B; Funding Stage Early Stage Venture; Money Raised . obfuscated. obfuscated. ... sionnatx.com — Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore …See details»